Schwentke et al. BMC Microbiology 2012, 12:107
http://www.biomedcentral.com/1471-2180/12/107




 RESEARCH ARTICLE                                                                                                                                  Open Access
 vitro vivo silencing plasmodial dhs eIf-5a genes putative, non-canonical
RNAi-related pathway
Andreas Schwentke1, Marcel Krepstakies2, Ann-Kristin Mueller3, Christiane Hammerschmidt-Kamper3,
Basma Motaal2, Tina Bernhard1, Joachim Hauber2 Annette Kaiser1*


  Abstract
  Background: Deoxyhypusine synthase (DHS) catalyzes step hypusine biosynthesis eukaryotic initiation
  factor 5A (eIF-5A) Plasmodium falciparum. Target evaluation parasitic DHS recently performed   CNI-1493, novel selective pro-inflammatory cytokine inhibitor used clinical phase II treatment   Crohn's disease. CNI-1493 prevented infected mice experimental cerebral malaria decreasing levels
  hypusinated eIF-5A serum TNF, implicating link cytokine signaling hypusine pathway.
  addressed question DHS itself eIF-5A required outcome severe
  malaria. set experiments performed vitro knockdown plasmodial eIF-5A DHS
  proteins RNA interference (RNAi) 293 T cells. Secondly, transfection siRNA constructs murine
  Plasmodium schizonts performed  turn, used infection.
  Results: 293 T cells treated plasmodial DHS- eIF-5A specific siRNAs control siRNAs analyzed   RT-PCR determine endogenous dhs  eIF-5A mRNA levels. expressed DHS-shRNA EIF-5A-shRNA
  clearly downregulated corresponding transcript cells. Interestingly, mice infected transgenic
  schizonts expressing eIF-5A dhs shRNA showed elevated parasitemia days post
  infection decreased intermittently. results obtained drug selection. Blood samples,
  taken infected mice day 5 post infection expressed EIF-5A-shRNA   DHS-shRNA analyzed RT-PCR Western blot techniques, demonstrating absence   hypusinated form eIF-5A DHS.
  Conclusions: Infection NMRI mice schizonts lethal P. berghei ANKA wildtype strain transgenic   plasmodial eIF-5A-specific shRNA DHS-specific shRNA resulted low parasitemia 2–9 days post infection   animals succumbed hyperparasitemia similar infections related non-lethal phenotype P. berghei
  strain NK65. RT-PCR Western blot experiments performed blood transfected erythrocytic stages
  showed genes important proliferation parasite.  experiments clearly
  demonstrate hypusine pathway Plasmodium linked human iNos induction.




* Correspondence: annette.kaiser@uk-essen 1
 University Duisburg-Essen, Medical Research Centre, Institute Pharmacogenetics, Hufelandstrasse 55, 45147 Essen, Germany list author information available end article

                                           © 2012 Schwentke et al.; licensee BioMed Central  Open Access article distributed terms                                            Creative Commons Attribution License (http://creativecommons.org/licenses 2.0), permits unrestricted use,
                                           distribution, reproduction medium, provided original work properly cited.
 Schwentke et al. BMC Microbiology 2012, 12:107                                                                  Page 2 13
http://www.biomedcentral.com/1471-2180/12/107




Background                                                    essential blood stages [9].  finding RNA interference (RNAi) evolutionary conserved          question standard disruption techniques showed
mechanism range eukaryotes,        effect parasitic development blood stages
plays key role post-transcriptional gene regulation      [10]. authors suggested RNAi protection genomes. process RNAi trig-       functional Plasmodium, cases resulted
gered recognition double-stranded RNA               parasitic death significant growth defects (dsRNA), processed 21–25 nucleotide        unspecific downregulation multiple genes RNAi.
sequences Dicer, cytoplasmic dsRNA specific RNa-            Deoxyhypusine synthase (DHS) catalyzes step
seII endonuclease [1]. generated RNAs associate           biosynthesis amino acid hypusine (Hyp), RNA-induced silencing complex (RISC)           novel amino acid present eukaryotic initiation factor
wind strand-specific manner [2]. resulting short     5A (eIF-5A) form deoxyhypusinylated intermedi-
interfering RNAs (siRNAs) target homologous              ate. DHS transfers aminobutyl moiety tria-
mRNA degradation combination RNase            spermidine є-amino group Lys50 present
H enzyme Argonaute (Slicer) [3]. stage double          hypusine loop. genes identified stranded (ds) RNA processing surpassed experi-      P. falciparum P. vivax [11,12]. Hitherto, bio-
mentally introducing sequence-specific siRNAs directly        logical function posttranslational modification cells.                                                   unknown. Recent studies implicated permissive
   Given immense Public Health costs malaria          role eIF-5AHyp various diseases. diabetes type 2
disease need new drug targets silencing ap-     pancreatic stressed ß-cells [13] HIV-infected T
proach employing RNAi extremely beneficial           cells, eIF-5AHyp functional nucleocytoplasmic development novel advanced therapeutic         shuttle protein transport translation spe-
strategies.  ability use RNAi gene        cific mRNAs [14].
silencing Plasmodium provide powerful means           Particularly HIV, eIF-5AHyp essential nucleo- gain insight pathogenic blood stages.                 cytoplasmic transport translation incompletely-
   Recent experiments performed molecular genetics         spliced mRNAs encoding viral proteins [15,16]. diabetes
suggested RNAi functional malaria para-        type2 eIF-5AHyp enables cytokine-mediated islet dysfunc-
sites [4]. authors showed expression        tion direct posttranscriptional regulation analyzed proteins continued despite application      mRNA encoding iNos2 (Nos2) rodent variety RNAi-based strategies target genes        human cells [13,17]. Importantly, immunological non-essential growth development          events lead severe malaria complex par-
P. falciparum P. berghei. good agreement, control       allel events present HIV-infection pancreatic
experiments Trypanosoma brucei, protozoan para-        stressed ß-cells. Exogenous administration [18,19]
site validated RNAi, successful. Furthermore,       prevents syndrome severe malaria. parasite determine primitive RNAi machinery exists        specific nitric oxide synthase does exist, defense Apicomplexa comparative analysis Apicomplexan         response attributed host specific iNos. protozoan genomes undertaken. Taken             Cerebral malaria (CM) characterized clinical fea-
gether data argued RNAi absent malaria       tures like cognitive dysfunctions, seizures, coma parasites [4].                                                clinical parameters like anemia, metabolic acidosis, renal
   studies,  reported successful appli-   insufficiency hypoglycaemia. 
cation RNAi gene silencing erythrocytic         standing malaria pathogenesis rudimentary, differ-
stages Plasmodium. series experiments        ent theories accepted understand performed introducing long dsRNAs electropor-           pathological process [20]. sequestration theory sug-
ation infected erythrocytes. Gissot coworkers        gests seizures caused adherence [5] performed silencing experiments MybB1, tran-       parasites red blood cells subsequent expression
scription factor Plasmodium demonstrating          parasite specific antigens turn lead essential role erythrocytic stage. Kumar       obstruction blood flow, cerebral hypoxia decreased
colleagues [6] showed similar manner requirement     removal waste. neurological symptoms serine-threonine phosphatase DNA-replication      growing evidence parasite-induced sequestration Plasmodium. Tuteja colleagues [7] identified signal     infected uninfected erythrocytes changes blood—
peptidase required intra-erythrocytic growth      brain barrier function.  host-specific immune RNAi. Apart electroporation [8], siRNAs          mechanisms important response pres- added directly culture medium. Cysteine      ence parasites CNS.
proteases falcipain-1 falcipain-2, necessary       step infection process parasitized red haemoglobin degradation, shown            blood cells adhere brain microvascular endothelial
 Schwentke et al. BMC Microbiology 2012, 12:107                                                             Page 3 13
http://www.biomedcentral.com/1471-2180/12/107




cells erythrocyte membrane protein [21].         contrast, control siRNA lacks complementary release merozoites parasitic glycosylphosphati-     sequences human genome did negatively
dylinositol (GPI) released induces local          affect abundance Plasmodium transcript inflammatory response involving natural killer sub-      expected size 612 bp (amino acid positions 208–
sequently CD4+ T cells. stage infection,      412) (lane 1). exclude target effects number
proinflammatory cytokines including tumor necrosis fac-      control experiments performed. positive
tor α (TNF-α interferon γ (IFN-γ interleukin  -1ß     control recombinant plasmodial DHS expression produced locally entry systemic        vector transfected 293T cells. Following
phase cytokines activate macrophages            RT-PCR cDNA fragment 612 bp detected
CD8+ T cells [21]. systemic phase, platelets     (lane 3). transcript observed untrans- microparticles released inducing perforin-           fected 293Tcells analyzed (lane 2).  ampli-
mediated lesions endothelium [21].                    fied human GAPDH sequence, representing   Recently, metabolic changes central nervous         housekeeping gene, control various cotransfec- caused parasite, characterized       tions. shown, presence expected GAPDH theory explaining pathology malaria.    amplificate detected analyzed samples CM increase lactate alanine concentra-      (Figure 1B), suggesting silencing effect tion alterations tryptophane metabolites like     DHS siRNA used specific dhs amplificate
kynurenine pathway lead increased permeability      does homology human orthologue. blood brain barrier plasma proteins.                 separate set experiments applied 4 different
  DHS recently validated druggable target      shRNAs knock eIF-5A precursor protein. small molecule CNI-1493, synthetic guanylhy-        pSilencer1.0-U6 vectors expressing different eIF-5A
drazone [22], significantly extends survival       shRNAs (#5, #6, #7, #18; Materials Methods
rate Plasmodium berghei ANKA-infected C57BL/6             (Additional file 1: Figure S1) individually
mice [22]. Initial studies compound suggested       cotransfected plasmodial eIF-5A expression vector mechanism action attributed     293T cells.  monitoring eIF-5A tran-
hibition parasitic DHS translation host spe-   script abundance performed RT-PCR. cific TNFα-mRNA [23], indicating link host         4 tested eIF-5A siRNAs shRNA #18 (Figure 2A,
cell proinflammatory cytokine production hypu-       lane 3) capable completely downregulating sine pathway.                                                plasmodial eIF-5A mRNA level 293T cells.   study outcome vivo knockdown            constructs vitro knockdown unsuccess- enzyme target protein eIF-5A          ful  data; shown).
erythrocytic stages Plasmodium                Control reactions non-transfected cells transfected siRNA constructs targeted             (Figure 2A, lane 1) eIF-5A shRNA #18 cotransfected
genes based vitro knockdown experiments           aquaporin-specific siRNA (Figure 2A, lane 4)
P. berghei ANKA schizonts, using standard transfection       did change silencing effect. eIF-5A methods [24].                                                highly conserved protein eukaryotes nucleic
                                                             acid sequence significantly divergent comparison
Results                                                      human orthologue amplificates vitro knock P. falciparum DHS eIF-5A          endogenous eIF-5A expected.  moni- RNAi                                                      tored presence GAPDH RT-PCR transfec- different DHS short hairpin RNAs (shRNAs), #43           tions (Figure 2B) independently presence #176  Materials Methods section), expressed      siRNA construct. pSilencer1.0-U6 vector applied knock           validate RT-PCR experiments limit DHS protein P. falciparum. shRNA           detection corresponding mRNAs e. eIF-5A
#43 targets dhs sequence nucleotide positions         dhs determined. Titrated dhs-specific mRNA
337–358, shRNA #176 targets dhs sequence        resulted limit detection 20 ng eIF-5A-
nucleotide positions 1269–1290 P. falciparum      specific mRNA detected concentra-
mRNA. constructs individually cotransfected        tion 200 ng. Optimal primer binding determined plasmodial DHS expression vector 293T cells        eIF-5A-specific primers cDNA concentration verify expected degradation dhs transcript.    130 ng dhs-specific primers cDNA concen- results obtained RT-PCR analysis signifi-      tration 650 ng (data shown). knock plasmodial dhs transcript             sum, data demonstrated Plasmodium-
shRNA P #176 construct (Figure 1A, lane 4), opposed       specific eIF-5A DHS sequences principal shRNA P #43 expressed (lane 5).           silenced RNAi.
 Schwentke et al. BMC Microbiology 2012, 12:107                                                                                    Page 4 13
http://www.biomedcentral.com/1471-2180/12/107




 Figure 1  Inhibition plasmodial DHS RNAi monitoring 612 bp amplificate RT-PCR transfection 293 T
 cells DHS expression vector. 293T cells cotransfected  1) Scramble II-duplex shRNA; 2) transfected DNA; 3)  recombinant pcDNA3 vector containing 612 bp -highly conserved region dhs gene P. falciparum (amino acid positions 208–412);
 4) DHS- shRNA construct P#176; 5) DHS- shRNA construct P#43. B) Analysis 983 bp GAPDH amplificate cotransfected 293T cells
 described Figure 1A.


Monitoring vivo silencing eIF-5A DHS                        disappearance respective transcripts, erythrocytic stages infection NMRI mice                    detection level assay. contrast, transgenic schizonts P. berghei                                     eIF-5A sequences clearly detected erythro- regard vitro results, investigated                     cytic stage infection schizonts, silencing effect expressed DHS-specific                   transfected dhs-specific shRNA #176 vector
eIF-5A specific shRNAs vivo rodent model                        (Figure 3A, lane 1). control reactions P. berghei ANKA strain [24]. Infection NMRI                        applied. RT-PCR reactions kanamycin control
mice P. berghei ANKA wild type strain leads                      RNA 1.2 kb (Figure 3A, lane 5) experimental cerebral malaria 6 10 days p.                   recombinant eIF-5A plasmid P. vivax moni- parasitemia range 3–5                     tored, resulting amplification products approxi-
infected erythrocytes. case infectious non                 mately 323 bp 448 bp, respectively (Figure 3A,
lethal phenotype P. berghei strain NK56, infected                    lanes 5 4). parallel confirmed quality mice succumb high parasitemia 80 days p                      total cellular RNA preparation presence cerebral malaria.                                                α-tubulin II sequences, expressed    step DHS-specific shRNA #176 eIF-5A-                    asexual blood stages Plasmodium (lane 4).
specific shRNA #18 expressed pSilencer 1.0-U6                         monitored effect vivo eIF-5A silen-
vector transfected schizonts, late develop-                 cing protein level. shown Figure 3B, eIF-5A
mental stage parasite. transgenic schizonts                 protein absent NMRI infected mice trans- applied NMRI mice infection. vivo gene                    genic schizonts expressing #18 eIF-5A-specific
silencing monitored animals’ erythrocytes                     shRNA. experiments polyclonal anti-eIF-5A day 2 post infection RT-PCR  Infection                   antibody raised highly conserved P. vivax schizonts containing eIF-5A-specific shRNA                      protein (96  identity) used. NMRI mice infected
#18 vector (Figure 3A lane 2) led complete                          transgenic schizonts expressing #176 DHS-




 Figure 2  Silencing parasitic EIF-5A RNAi 293 T cells subsequent monitoring RT-PCR. cotransfection performed
  1) transfected DNA; 2) recombinant, plasmodial eIF-5A expression plasmid 483 bp cDNA; 3) EIF-5A-shRNA construct P#18;
 4) aquaporin-5-specific siRNA. B) 983 bp GAPDH amplificate used internal control transfected mammalian cell line.
 Schwentke et al. BMC Microbiology 2012, 12:107                                                                                           Page 5 13
http://www.biomedcentral.com/1471-2180/12/107




 Figure 3  Monitoring vivo silencing parasitic eIF-5A RT-PCR RBCs infected NMRI mice 2 days post infection. NMRI
 mice infected transgenic schizonts harbouring expressed shRNA P#18. M1) 1 kb ladder (LifeTechnologies, Karlsruhe, Germany);
 1) non-transfected 293T cells 2) EIF-5A-siRNA; 3) positive control quality cellular RNA 548 bp amplificate generated  α-tubulin gene-specific primers P. berghei; 4) PCR-control reaction eIF-5A-gene specific primers P.vivax generates 448 bp cDNA
 fragment; 5) Amplificate 323 bp obtained RT-PCR control reaction 1.4 kb kanamycin mRNA; M2) 100 bp ladder (Life Technologies,
 Karlsruhe, Germany). B) Western Blot analysis parasitic sh-eIF-5A expression transgenic schizonts infection NMRI mice. Protein
 extracts generated  1) shEIF-5A RNA #P18; 2) shDHS-RNA; #P176; 3) protein extract RBCs infected P. berghei ANKA strain  4) mock strain  transfected shRNA); 5 6) different protein concentrations EIF-5A histidine-tagged, purified protein. 7) Standard
 protein marker (Roth). Polyclonal-antibody EIF-5A protein P. vivax applied concentration 1:1000 detected  protein band molecular weight 20 kDa. protein concentrations extracts 10 μg/μl. C) Confirmation specificity  used anti-eIF-5A antibody Western Blot analysis. 1) Protein extract prepared NMRI infectected mice expressing #18 eIF-5A-specific
 shRNA, supplemented recombinant eIF-5A protein P.vivax; 2) purified, recombinant EIF-5A protein P.vivax; 3) Protein extract
 prepared NMRI infected mice expressing #18 eIF-5A-specific shRNA. protein concentration 10 μg lane.


specific shRNA construct showed unmodified                          infected NMRI mice expressing #18 eIF-5A-specific hypusinated eIF-5A protein present (Figure 3B,                        shRNA spiked purified eIF-5A protein lane 2). result implies #176 DHS-specific                      P. vivax (Figure 3C, lane 1). P. vivax anti-eIF5A
shRNA construct exclusively affects DHS protein.                         antibody clearly detected EIF-5A protein eIF-5A modified abundant                       respective extract (lane 1) EIF-5A protein ab- unhypusinated form, recognized poly-                     sent crude extract P. berghei ANKA strain
clonal anti-eIF-5A antibody (Figure 3B, lane 2).                         (Figure 3C, lane 3).  purified, recombinant
results support observation RNA                      eIF-5A protein clearly recognized antibody
coding eIF-5A gene present erythrocytic                        (Figure 3C, lane 2). data suggest vivo
stages infection schizonts expressing                         knockdown eIF-5A possible.
DHS-shRNA #176 (Figure 3A, lane 4). polyclonal                             DHS-specific RT-PCR performed control
antibody detected eIF-5A protein size                          formation 1248 bp cDNA fragment 17,75 kDa P. berghei ANKA strain (Figure 3B, lane                     erythrocytic stages infection NMRI mice 3) mock control strain (Figure 3B, lane                    transgenic schizonts harbouring DHS-shRNA #176
4), eIF-5A protein P. vivax displayed                     eIF-5A #18 construct (Figure 4A, lanes 1–2). expected molecular mass approximately 20 kDa (lanes                       dhs-specific transcript detectable #176-
5 6).                                                                    infected (shRNA expressing) erythrocytes (lane 1),   support specificity polyclonal                       present #18-infected (shRNA expressing)
anti-EIF-5A antibody, protein extracts obtained                     erythrocytes (lane 2) control reaction  Schwentke et al. BMC Microbiology 2012, 12:107                                                                                        Page 6 13
http://www.biomedcentral.com/1471-2180/12/107




 Figure 4  Monitoring vivo knockdown P. berghei infected schizonts transgenic expressed plasmodial DHS shRNA  RT-PCR days post infection NMRI mice. NMRI mice infected transgenic schizonts transfected plasmodial shRNA
 P#176 construct. M1) 1 kb ladder (LifeTechnologies, Karlsruhe, Germany); 1) DHS-shRNA; 2) EIF-5A-shRNA; 3) Amplification recombinant
 pcDNA3 vector carrying dhs gene P. falciparum generates cDNA fragment 1491 bp. 4) Quality control total, cellular RNA  amplification 548 bp fragment α-tubulin gene-specific primers P. berghei; 5) PCR-control recombinant eIF-5A (448 bp) expression
 vector eIF-5A primers; M2) 100 bp ladder (LifeTechnologies, Karlsruhe, Germany) B) vivo silencing plasmodial DHS monitored  Western blot analysis infection NMRI mice transgenic schizonts expressing shDHS. 1 2) different concentrations purified,
 human DHS protein; 3) PB ANKA wild type strain protein extract 4) Mock strain protein extract; 5) eIF-5A shRNA P#18; 6) DHS- shRNA P#176. C)
 Validation anti-DHS antibody specificity crude protein extracts prepared infection NMRI mice expressing plasmodial DHS #176 shRNA
 construct. M) Blueeye Marker; 1) crude protein extract infected NMRI mice plasmodial DHS #176 shRNA construct supplemented
 recombinant human protein; 2) crude protein extract infected NMRI mice plasmodial DHS #176 shRNA construct; 3) purified
 recombinant human DHS protein. protein concentration 10 μg lane.


plasmodial dhs-specific primers (lane 3). Additionally,                    amino acid identity P. vivax orthologue 56  quality cellular RNA confirmed P.                      identity P. berghei. highly conserved amino acid
berghei specific α-tubulin primers (lane 4) reverse                     regions apparently recognized human anti-
transcription using 1.2 kb Kanamycin-mRNA (lane 5).                      body. Protein extracts prepared infection parallel controlled vivo silencing DHS levels                  P. berghei (lane 3) mock strain (lane 4) showed Western blot analysis (Figure 4B). polyclonal anti-                   expected 49 kDa orthologue DHS. DHS DHS antibody raised human DHS protein                          completely abundant eIF-5A-shRNA mutant #18
detected predicted size 41 kDa different                       (lane 5) faint band visible DHS-shRNA
concentrations purified human DHS applied                          mutant (lane 6), cDNA detected (lanes 1 2). Results amino acid alignment                      RT-PCR reaction.
showed human DHS isoform1 shares 57  amino                                performed eIF-5A, specifi-
acid identity P. falciparum 3D 7 orthologue, 58                     city human anti-DHS antibody confirmed.
 Schwentke et al. BMC Microbiology 2012, 12:107                                                                      Page 7 13
http://www.biomedcentral.com/1471-2180/12/107




Protein extracts prepared infected NMRI mice                Studies effect cytokines iNos production harbouring expressed sh-RNA construct #176                  posttranslational modification eIF-5A
supplemented recombinant, human DHS protein                     investigate possible link cytokine signal-
(Figure 4C, lane 1). human anti-DHS antibody                     ing translation iNos2 mRNA host,
clearly detected recombinant human protein (lane 3)              Western blots performed protein extracts added DHS protein (lane 1).                   serum infected erythrocytic stages NMRI
extract plasmodial shRNA #176 DHS signal                  mice. Figure 6 shows signals iNos2 absent absent (lane 2). data demonstrate validity             serum p.  DHS silencing construct P #176 antibody.                                                    eIF-5A-shRNA construct P #18 (Figure 6, lanes 1
                                                                     2), iNos2 protein molecular size Monitoring parasitemia infection schizonts                  approximately 131 kDa detectable P. berghei
transfected eIF-5A- DHS-specific siRNA                      ANKA strain infected erythrocytes (Figure 6, lane 3). respect vitro silencing data, P. berghei puri-        notably, prominent signals iNos2 protein fied schizonts transfected eIF-5A               detected immortalized T cells (Jurkat cells) (Figure 6,
shRNA construct (P #18) DHS shRNA (P #176)                lane 4 uninduced lane 5 induced) monocytic
struct. cases, transfected cells tracked         cell line (Mono Mac) (Figure 6, lane 6). signal fection recipient outbred NMRI mice                   obtained HeLa cells (lane 7).
selection pressure.                                                     difference signal intensity    independent, different sets experiments                 induced uninduced cells probably induc-
infection mice monitored transfection                tion ionomycin/PMA (phorbol 12-myristate 13-
recombinant schizonts expressing P #176 DHS-              acetate), correct inductor shRNA, P #18 construct (eIF-5A-shRNA) (Figure 5).             stimulate cytokine cell signaling. control, infection performed using mock                   support results nitric oxide quan-
strain, transfected DNA. day 2               tified colorimetric assay enzymatic conver- day 10 post infection, parasitemia significantly              sion nitrate nitrite enzyme nitrate reductase
lower lines compared untransformed mock               followed detection nitrite colored azo dye
strain. contrast, mock strain displayed parasitemia         product. formed nitrite nitrate 9  day 6 post infection, compared transfected           nitric oxide approximately 20-fold lower parasites DHS-shRNA (4.5 ) eIF-5A-                   serum infection mice shRNA construct
shRNA. 9 days post infection, parasitemia increased            P #18 (108,8 μM/L) (Table 1) 18-fold lower significantly infection experiments, harbouring ei-          shRNA construct P #176 (120 μM/L) (Table 1) com-
ther transgenic schizonts DHS-shRNA              parison wild type (2260,5 μM/L).
eIF-5A-shRNA.
                                                                     Discussion
                                                                     Hitherto, biological function unusual amino
                                                                     acid hypusine studied Plasmodium. Pre-
                                                                     vious studies showed hypusination eIF-5A im-
                                                                     portant cell proliferation parasite [11].
                                                                     Deoxyhypusine synthase (DHS), catalyzes                                                                      step hypusine pathway recently targeted
                                                                     small molecule inhibitor, CNI-1493, blocked
                                                                     parasitic growth vitro vivo [22]. excel-
                                                                     lent way study biological function post-
                                                                     translational modification genetic
                                                                     analysis loss function proteins involved  Figure 5 Parasitemia outbred infected recipient mice post        hypusine biosynthesis.
 transfection schizonts transgenic parasitic eIF5A-           future important issue pursue
 shRNA DHS-shRNA. Infection construct                                                                      targeted, stable gene disruption dhs eIF-
 performed different independent experiments mice
 condition. Pale blue triangles blue points represent    5Agenes Plasmodium, exact function  curves determined parasitemias post infection      erythrocytic life cycle stages unknown.  shDHS P#176 mice. Pale blue upside triangles blue   date gene disruption insertion strategy suc-
 squares represent monitored parasitemia expressed      cessfully shown rodent model P. berghei  eIF5A-sh P#18. parasitemia mock control strain                                                                      partly working intraerythrocytic schizogeny
 represented pale blue dot pale blue rhomb.
                                                                     P. falciparum [24,25].
 Schwentke et al. BMC Microbiology 2012, 12:107                                                                                         Page 8 13
http://www.biomedcentral.com/1471-2180/12/107




  Figure 6 Cytokine signaling human iNos2 translation dependent hypusine pathway infection Plasmodium.
  Western Blot analysis performed equal amounts protein (10 μg) extracted infected erythrocytic stages transgenic
  schizonts P. berghei ANKA strain 1) protein extract prepared serum infection schizonts harbouring expressed plasmodial
  DHS-shRNA 2) eIF-5A-siRNA expression construct; 3) P. berghei ANKA strain; 4) induced 5) non- induced Jurkat cells; 6) Mono Mac 1
  cells; 7) HeLa cells; M) Standard protein marker Roth, St. Leon, Germany. Detection iNos2 protein molecular size 131 kDa   performed human anti-Nos2 antibody dilution 1:1000.


  understanding cerebral malaria (CM) patho-                          performed showing 50  reduction expression
genesis rudimentary [26]. results clearly dem-                  level berghepains homologues cysteine
onstrate hypusine pathway Plasmodium                             proteases Plasmodium [27]. siRNA experi-
supports different hypotheses patho-                     ments, strategy reduce gene expression cultured
genesis cerebral malaria e. sequestration theory                    cell lines pSilencer1.0-U6 vectors producing inflammation hypothesis. underlying                       respective shRNAs U6 promotor selected.
mechanisms cerebral malaria pathogenesis                             data indicate vitro knockdown eIF-
adherence parasitized red blood cells vascular                         5A different shRNAs completely ablat-
endothelial cells parasite specific proteins. Infected                    ing eIF-5A expression shRNA # P18 NMRI mice transfected schizonts transgenic                          293 T cells (Figure 2A, lane 3) markedly reduced
plasmodial eIF-5A- DHS-specific shRNA showed                            eIF-5A transcript level. shRNA 
50  reduced parasitemia comparison untrans-                        structs eIF-5A targeted eIF-5A
fected control 2 9 days post infection.                       sequence. eIF-5AshRNA #18, targets posi- indicate preventing parasitic sequestration.                      tions 163–184 eIF-5A nucleic acid sequence,
  approach test possibility                      caused complete decrease eIF-5A mRNA levels.
knockdown DHS precursor protein eIF-5A                         results agreement structural model
possible Plasmodium, vitro knockdown RNAi                        human eIF-5A1 [30], consists domains, performed unequivocal demonstration                        basic N-terminal domain hypusine loop Plasmodium genome contains conserved                          acidic -terminal domain connected hinge.
RNAi machinery genes enzymes date missing.                          basic N-terminus, hypusine modification past, RNAi circulating malaria parasites                       covers amino acid positions 46–54  e. nucleic acid posi-
                                                                             tions 138–162 close 3’ prime end
Table 1 Colorimetric determination nitric oxide                           hypusine loop.
formation nitrate nitrite sera infected                         contrast eIF-5A shRNA #7 targets position 115–
mice obtained P.berghei ANKA strain infection                      136, proximal 5’-end loop, does infection schizonts harbouring expressed                      affect mRNA abundance. likely second-
plasmodial DHS shRNA #176 plasmodial EIF-5A                               ary structure hypusine loop position shRNA #18                                                                    block degradation specific mRNA [28]. Taken
Nitrate nitrite [μmol/L]                   Wild type transfectants    tested shRNAs,  eIF-
2200,5                                         P. berghei ANKA wild type     5A-specific shRNA #18 caused considerable decrease
120                                            DHS-specific shRNA # 176      eIF-5A transcript vitro.
109                                            EIF-5A-specific shRNA # 18      DHS-shRNAs, #43 #176, targeting nucleotide
Nitrate nitrite determination infection mice transgenic
                                                                             positions 337–358 bp 1269–1290 bp, respect-
schizonts expressing plasmodial DHS EIF-5A shRNAs.                       ively, employed vitro knockdown DHS
 Schwentke et al. BMC Microbiology 2012, 12:107                                                                   Page 9 13
http://www.biomedcentral.com/1471-2180/12/107



 Plasmodium. Surprisingly, DHS-shRNA                shRNA mutants P #176 (DHS) P #18 (EIF5A) struct #176 successful downregulate dhs tran-        18-fold 20-fold lowered formation nitric oxide.
script significantly (Figure 1A, lane 5),          findings prove link targeted sequence did cover active site          hypusine pathway iNos production broaden
enzyme amino acid region Lys287              understanding CM malaria pathology Glu323 [28,29].                                             implicate alternative strategies therapy. Similar results
   Subsequently, monitoring vivo silenced P. berghei      obtained DHS heterozygous knockout
blood stage parasites transgenic eIF-5A-             mice attenuated cytokine signalling evidenced shRNA DHS-shRNA post transfection performed              reduced nitric oxide synthase production [31]. RT-PCR. case eIF-5A-shRNA containing                  Malaria patients present hypoargininemia
blood stages eIF-5A transcript present              [32], metabolomic studies Plasmodium falcip-
(Figure 3A, lane 2), erythrocytes DHS-        arum 48 h intraerythrocytic life cycle reveal
shRNA (Figure 3A, lane 2) dhs cDNA abun-            nearly complete depletion L-arginine levels. Nitric
dant (Figure 4A, lane 1).  eIF-5A transcript        oxide synthase induced arginine catalyzes detectable, suggesting silencing effect         reaction nitric oxide   urea.  cere- specific.                                                bral malaria lack nitric oxide     results confirmed Western            presence parasite-specific arginase leads blot analysis 17,75 kDa eIF-5A protein            depletion arginine subsequent downregulation absent transgenic P. berghei ANKA parasites har-         host-specific nitric oxide synthase. allow bouring eIF-5A-specific siRNA. proteins, e.          parasite evade dependent immune response P. falciparum P. berghei homolog share              host deleterious parasite proliferation
amino acid identities 73 . control experiment           [33]. Plasmodium berghei ANKA infection antibody raised eIF-5A protein             mice exogenous nitric oxide decreases brain vascular
P. vivax crossreacted eIF-5A homologue            inflammation, leakage venular resistance [17,18] mock strain P. berghei ANKA strain result-          protects cerebral malaria.
ing protein 17,75 kDa [30] (Figure 3B, lanes 3             Finally, crystal structure Plasmodium arginase 4). monitor suppressed DHS expression poly-            resolved recently indicates low complex-
clonal human antibody applied detected                ity region [33] largely disordered dele- P. berghei orthologue 49 kDa (Figure 4B, lanes 3         tion does significantly compromise enzyme activity. 4) mock control P. berghei ANKA               disruption P. falciparum arginase led strain. contrast faint band detected DHS        apparent reduction liver stage infection.
siRNA mutant suggesting gene silenced completely.                                            Conclusions
   inflammation hypothesis cerebral malaria im-          previously suggested RNAi plies brain damage result inflammatory         functional Plasmodium, putative, non-canonical
response human host parasite central       RNAi pathway exist malaria parasites. vivo
nervous (CNS). production proinflamma-            knockdown eIF-5A DHS expression shRNAs
tory cytokines like 1β, TNF-α, IFN-γ leads secre-         infection rodent model decreased parasitemia
tion nitric oxide kills parasite.      intermittently development cerebral malaria.
recently reported hypusinated eIF-5A required        data similar related non-lethal pheno- nuclear export translation iNos-            type P. berghei ANKA NK 65. results encoding mRNAs pancreatic, stressed ß-cells            study function hypusine modifi-
release proinflammatory cytokines [17]. test         cation respect malaria infection therapy.
hypothesis host iNos2 protein levels monitored serum infection P. berghei ANKA strain        Materials methods transfected shRNAs P #176 (DHS) P #18               Ethics statement
(EIF5A), parasitic nitric oxide synthase absent.     animal experiments performed FELASA clearly demonstrate mutants               category B GV-SOLAS standards. Animal experi- response cellular stress e. induction    ments approved German authorities (Regierung-
ducible nitric oxide synthase (iNos2) human host         spräsidium Karlsruhe, Germany). modification eIF-5A interrupted silencing parasitic DHS eIF-5A.  nitric oxide        siRNAs (small interfering RNAs) targeting DHS eIF-5A
synthase induced 20-fold infection wild       following double stranded siRNAs used type P. berghei ANKA strain comparison                synthesized Ambion, Karlsruhe, Germany: RNAi  Schwentke et al. BMC Microbiology 2012, 12:107                                                             Page 10 13
http://www.biomedcentral.com/1471-2180/12/107




DHS EIF5A knockdowns, siRNA duplexes               Cloning length dhs cDNA eIF-5A cDNA used obtained annealing RNA               eukaryotic pcDNA3 vector
oligonucleotides synthesized Ambion, Karlsruhe,          Amplification dhs gene performed Germany. oligonucleotides (3000 mM dhs,             recombinant pet-Blue1 plasmid (Novagen, Darmstadt,
1500 mM eIF-5A) phosphorylated reaction       Germany) Plasmodium falciparum primers
volume 20 μl 3 Units polynucleotide kinase          containing recognition sites EcoRI (restriction site
(10 U/μl) (Roche Diagnostics, Penzberg, Gemany)          underlined) dhs forward 5’-TTTGAATTCATGGTG
37°C 45 min. reaction stopped ice        GATCACGTTTC-’3’ NotI dhs reverse 5’- TTT
1 min. annealing reaction performed 95°C          GCGGCCGCTCACATATCTTTTTTCCTC- 3’. result- subsequent cooling reaction room             ing fragment 1491 bp digested EcoRI temperature overnight.                                      NotI ligated EcoRI/NotI treated pcDNA3 vector
  annealing siRNA duplexes cloned       (Invitrogen, Darmstadt, Germany) sequenced. pSilencer 1.0-U6 vector transfection 293T       construction eIF-5A cDNA containing pcDNA3
cells schizonts.                                         vector, eIF-5A nucleic acid sequence amplified
  DHS knockdown #43, RNA oligonucleotides           recombinant plasmid pSTBlue-1 Acceptor™ vector
5’- UGUUAGUGAAGAUCUUAAUtt-3’ 5’-AUUAA                   (Novagen, Darmstadt, Germany) primers containing
GAUCUUCACUAACAtt-3’ applied targeting              EcoRI eIF-5Aforward 5’ -AAA GAA TTC ATG TCA
nucleotide positions 337–358 plasmodial dhs          GAC CAC GAA AC-3’ NotI eIF-5Areverse 5’-TTT
cDNA. DHS knockdown #176, RNA oligo-                GCG GCC GCC TAG GAG GAC AAC TCC-3’ restric-
nucleotides 5’- UGAGGAAUGGUGCUGAUUUtt-3’                tion sites.
5’-AAAUCAGCACCAUUCCUCAtt-3’ applied targeted nucleotide positions 1269–1290 dhs cDNA.    Cotransfection pSilencer1.0-U6 vectors 293 T cells
  eIF-5A knockdowns 4 different siRNA               6 microtiter plate 7x105 293T cells seeded
duplexes generated. EIF-5A knockdown           6 wells. different sets cotransfections #5, RNA oligonucleotides 5’- ACGGCCACGUGAUG                 performed: DHS;  P. falciparum dhs cDNA pcDNA3
CUAAAtt-3’ 5’- UUUAGCAUCACGUGGCCGUtt-3’                 (0.3 μg), ii) P. falciparum dhs cDNA pcDNA3 applied targeting nucleotide positions 81–102   premade scramble II duplex negative control siRNA
P. vivax eIF-5A cDNA. EIF-5A knockdown #6,          (1.0 μg), iii) P. falciparum dhs cDNA pcDNA3 RNA oligonucleotides 5’- AGGAGCAUCCUUGCAAA                  DHS- specific shRNA construct #43 (1.0 μg), iv) P. fal-
GUtt-3’ 5’- ACUUUGCAAGGAUGCUCCUtt-3’               ciparum dhs cDNA pcDNA3 DHS-specific
applied targeted nucleotide positions 99–120;     shRNA construct #176 (1.0 μg). various transfec-
EIF-5A knockdown #7, RNA oligonucleotides 5’-AGUG           tions mixed transfection mix (total vol.
GUAGAUUACUCCACGtt-3’ 5’- CGUGGAGUAAU                    400 μl), contained Opti-MEMW (Invitrogen,
CUACCACUtt-3’ used targeting nucleotide            Karlsruhe, Germany) polyethylenimine (PEI) (4 μl/
positions 115–136. eIF-5A knockdown #18, RNA oli-       μg), added cultures. 10 min gonucleotides 5’- CUGAGUUGCAGCUGAUUGAtt-3’                  incubation room temperature, culture superna- 3’- UCAAUCAGCUGCAACUCAGtt-5’ applied               tants substituted 2 ml DMEM (Dulbecco's targeted eIF-5A gene nucleotide positions      Modified Eagle's Medium) (Invitrogen, Karlsruhe, Ger-
163–184.                                                     cell cultures incubated overnight                                                             37°C. day, medium changed supple-
                                                            mented streptomycin (60 μg/ml). Prior transfec-
Construction pSilencer1.0-U6 vector double          tion, cells washed PBS-buffer (phosphate
stranded siRNA DHS eIF-5A                            buffer saline).
20 μg (Ambion/Invitrogen, Karlsruhe, Germany)          Cotransfection P. falciparum eIF-5A pcDNA3-
double digested EcoRI/ApaI (20 U) reaction        based expression vector combination 4 different
volume 20 μl dephosphorylated calf intestine    sets siRNA vectors performed according alkaline phosphatase (CIP) (MBI Fermentas, St. Leon         protocol Invitrogen (Karlsruhe, Germany):  P. fal-
Rot, Germany) (1 U/μl) 1 hour 37°C. double       ciparum eIF-5A expression vector (0.3 μg) digested vector gel-purified according Mini      aquaporin-5 specific-siRNA (2.7 μg) ii) P. falciparum
Elute Gel Extraction Kit protocol Qiagen, (Hilden,     eIF-5A expression vector (0.3 μg) eIF-5A-specific
Germany). Ligation annealed oligos           shRNA construct #18 (2.7 μg), iii) P. falciparum eIF5A
formed ligation kit Roche Diagnostics,        expression vector (0.3 μg) eIF-5A-specific shRNA
(Penzberg, Germany). Positive constructs analysed      #6 (2.7 μg), iv) P. falciparum eIF-5A expression vector double digestion ApaI HindIII.               (0.3 μg) eIF-5A shRNA construct #7 (2.7 μg), v)
 Schwentke et al. BMC Microbiology 2012, 12:107                                                               Page 11 13
http://www.biomedcentral.com/1471-2180/12/107




P. falciparum eIF-5A expression vector (0.3 μg) eIF-      applied blood anticoagulant accord-
5A shRNA #5 (2.7 μg).                                         ing protocol Proimmune [35].

Isolation cellular RNA                                     Western blot analysis
Isolation total cellular RNA performed according       Western blots performed using Blot dry blot- RNeasy Plant Mini Kit (Qiagen, Hilden, Germany).       ting device Invitrogen (Karlsruhe, Germany) quality isolated RNA verfied agarose        5 min 5.5 amp 25 V. Protein extracts gel electrophoresis quantity purity           blood stages transfected parasites resuspended determined UV spectrometry.                                1-fold Nupage buffer (Invitrogen, Karlsruhe, Germany)
                                                              boiled loaded 12  SDS-polyacrylamide gel.
RT-PCR analysis eIF-5A DHS silencing vitro      Immunodetection performed according proto- vivo                                                       col immunodetection kit Amersham monitor silencing eIF-5A DHS, RT-PCR            (Munich, Germany). Polyclonal anti-eIF5A antibodies performed according protocol Access-        (Eurogentec, Cologne, Germany) raised Quick™ RT-PCR (Promega, Mannheim, Ger-                 eIF-5A P. vivax anti-DHS antibodies . RT-PCR reaction gene specific primers          P. falciparum DHS applied dilutions 1:1000 eIF-5Aforward 5’-ATGTCAGACCACGAAACGT-3’/                  1:5000, respectively. Previous results shown eIF-5A reverse 5’-CTAGGAGGACAACTCCTTCACC                      human DHS protein cross-reacts P. berghei
GC- 3’ dhs forward 5’-ATAGTGCCTAATGA                      DHS protein highly conserved regions TAATTA -3’/dhs reverse 5’-AACCTCCTCCGAGAA                     overall amino acid identity 56   results
TAATAATACCAG -3’ used. control, human                section) [11]. Dilutions 1:1000 1:5000 GAPDH-specific sequences amplified using             antibody raised eIF-5A P. vivax following primers: GAPDH forward 5’-ATGGGGAAG                 used, proteins e. eIF-5A P. vivax GTGAAGGTCGG-3’ GAPDH reverse 5’-TTACTC                    P. berghei, share 97  amino acid identity [11].
CTTGGAGGCCATGTGG-3’. RT-PCR reactions
monitoring cDNA formation vivo experiments              Induction HeLa, jurkat monomac cells P.berghei infection following P. berghei-specific   preparation protein extracts
PCR primers used: eIF-5A forward 5’-ATGTCA               HeLa, Jurkat Monomac maintained Dulbec-
GACCACGAAACGT-3’/eIF5A reverse 5’- TATGATGA                   s modified Eagle medium (DMEM) (Sigma Aldrich,
CATTTCTTTAAGC-3’ dhs forward 5’-ATGGAT                    Munich, Germany), supplemented 10  (v/v) fetal
GGGGTATTCAAAGA-3’/dhs reverse 5’-CTAATCACT                    bovine serum (FBS), L-glutamine (2 mM), sodium pyru-
TTTTTCTCCTTTT-3’. analyze quality               vate (1 mM) penicillin (50000 U/ml) streptomycin
cellular total RNA α-tubulin forward 5’-ATGAGA              (5 mg/ml)).
GAAGTAATAAGTAT-3’ α-tubulin reverse 5’-TGT                  stress induction HeLa, Jurkat Monomac cells
TGATAAAACTGAATTAT-3’ primers applied,                    grown overnight cultures starving condi-
resulting specific α-tubulin fragment 548 bp.         tions  e. 1  FCS-containing medium).  cul-
                                                              ture supernatants substituted DMEM
Plasmodium transfection using shRNA expressing vectors        containing 10  FCS cells incubated Parasite transfection using sh expression vectors     3 hours. Finally, cell cultures exposed 4 hours
Pyrimethamine selection performed described            50 ng/mL phorbol 12-myristate 13-acetate (PMA) [24].                                                      1 μM calcium ionophore ionomycin. Subse-
                                                              quently, respective cell cultures washed Preparation protein extracts transfected              times PBS.
P. berghei parasites                                            total 106-107 cells lysed CelLytic M solu- detect eIF-5A DHS expression transfected            tion (Sigma Aldrich, Munich, Germany) 15 minutes wildtype P. berghei parasites, intraerythrocytic stages   rocker platform. lysed cells centrifuged purified CF11 Cellulose (Whatman) (Millipore,         12,000-20,000 x g pellet cellular debris. Schwalbach, Germany) remove platelets leuko-           supernatant, containing cell lysate, used fur-
cytes. Parasites lysed 0.2  saponin resus-        ther analysis.
pended PBS (LifeTechnologies/Invitrogen, Karlsruhe,
(Germany). determination protein concen-         Determination total nitric oxide
tration Bradford assay [34], extracts adjusted     Concentrations nitric oxide determined col- protein concentration (20 μg) PBS. Alter-       orimetric detection according kit protocol natively, detection iNos protein, serum        Enzo Life Sciences. Nitric oxide converted nitrate
 Schwentke et al. BMC Microbiology 2012, 12:107                                                                                                         Page 12 13
http://www.biomedcentral.com/1471-2180/12/107



 reduced nitrite enzyme nitrate reduc-                            9.    Dasaradhi PV, Mohammed  Kumar  Hossain MJ, Bhatnagar RK, Chauhan
tase followed colorimetric detection nitrite                               VS, Malhotra P: role falcipain-2, principle cysteine proteases                                                                                           Plasmodium falciparum merozoite egression. Biochem Biophys Res
coloured azo dye product absorbs visible light                                   Commun 2005, 336:1062–1068.
560 nm. determination allows determination                               10.   Sijwali PS, Rosenthal PJ: Gene disruption confirms critical role nitric oxide products nitrate nitrite.                                           cysteine protease falcipain-2 haemoglobin hydrolysis Plasmodium
                                                                                          falciparum. Proc. Natl. Acad. Sci. USA 2004, 101:4384–4389.
                                                                                    11.   Kaiser  Gottwald  Maier W, Seitz HM: Targeting enzymes involved Additional file                                                                           spermidine metabolism parasitic protozoa possible new strategy                                                                                           anti-parasitic treatment. Parasitol Res 2003, 91(6):508–516.
                                                                                    12.   Njuguna JT, Nassar M, Hoerauf  Kaiser AE: Cloning, expression  Additional file 1: Figure S1. Unsuccessful silencing parasitic
                                                                                          functional activity deoxyhypusine synthase Plasmodium vivax.
 EIF-5A RNAi 293T cells subsequent monitoring RT-PCR.
                                                                                          BMC Microbiol 2006, 6:91–96. 16.
 cotransfection performed  lane 1) EIF-5A-shRNA construct P#
                                                                                    13.   Maier B, Ogihara T, Trace AP, Tersey SA, Robbins RD, Chakrabarti SK,
 5; lane 2) EIF-5A-shRNA construct P#; lane 3) EIF-5A-shRNA construct P# 7;
                                                                                          Nunemaker CS, Stull ND, Taylor CA, Thompson JE, Dondero RS, Lewis EC,
 lane 4) pcDNA3 based plasmodal EIF-5A expression vector; lane 5) P.
                                                                                          Dinarello CA, Nadler JL, Mirmira RG: unique hypusine modification  falciparum eIF-5A expression vector aquarin-5 specific siRNA; lane 6)
                                                                                          eIF5A promotes islet beta cell inflammation dysfunction mice.
 EIF-5A-shRNA construct P# 18.
                                                                                          J Clin Invest 2011, 20(6):2156–2170.
                                                                                    14.   Hauber  Bevec D, Heukeshoven J, Krätzer F, Horn F, Choidas  Harrer T,
Competing interests                                                                       Hauber J: Identification cellular deoxyhypusine synthase novel authors declare competing interests.                                target antiretroviral therapy. J Clin Invest 2005, 115(1):76–85.
                                                                                    15.   Bevec D, Kappel B, Jaksche H, Csonga R, Hauber J, Klier H, Steinkasserer 
Authors’ contributions                                                                    Molecular characterization cDNA encoding functional human
MK involved transfection experiments, responsible               deoxyhypusine synthase chromosomal mapping RT-PCR Western Blot experiments. AKM CHS performed P.                         corresponding gene locus. FEBS Lett 1996, 378(2):195–198.
berghei transfection. BAM TB involved cloning siRNA              16.   Hofmann W, Reichart B, Ewald  Müller E, Schmitt  Stauber RH, Lottspeich
oligonucleotides. AK participated practically colorimetric assays              F, Jockusch BM, Scheer U, Hauber J, Dabauvalle MC: Cofactor requirements
Western Blot experiments, prepared manuscript organized financial                 nuclear export Rev response element (RRE)- constitutive
support, AKM JH critically appraised manuscript. thank Barbara                 transport element (CTE)-containing retroviral RNAs. unexpected role
Langer excellent technical assistance. authors read approved              actin. J Cell Biol. 2001, 152(5):895–910.
final manuscript.                                                                   17.   Maier B, Tersey SA, Mirmira RG: Hypusine: new target therapeutic
                                                                                          intervention diabetic inflammation. Discov. Med. 2010, 10(50):18–23.
Acknowledgements                                                                    18.   Zanni GM, Cabrales P, Barkho W, Frangos J, Carvalho L: Exogenous nitric work supported main parts grant German                           oxide decreases brain vascular inflammation, leakage venular
Academic Exchange Service (DAAD) AK (432/lz (2006).                                    resistance Plasmodium berghei ANKA infection mice.
                                                                                          J Neuroinflamm. 2011, 66(Zanni GM, Cabrales P, Barkho W, Frangos J,
Author details                                                                            Carvalho L):1–9. 8.
1
 University Duisburg-Essen, Medical Research Centre, Institute                   19.   Hawkes M, Opoka R, Namasopo S, Miller C, Thorpe KE, Lavery JV, Conroy AL,
Pharmacogenetics, Hufelandstrasse 55, 45147 Essen, Germany. 2Heinrich                     Liles WC, J